ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicHarnessing Macrophage Modulation: Advancing Hematologic Cancer Treatment StrategiesView all 7 articles
Unveiling the novel value of TREM1 in the proneural-mesenchymal transition of glioma via tumour-associated macrophages
Provisionally accepted
- 1First People’s Hospital of Chuzhou, Chuzhou, China
- 2Guangzhou University of Chinese Medicine, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Tumour-associated macrophages (TAMs) constitute the most abundant immune cell population in the glioblastoma (GBM) tumour microenvironment. These macrophages critically influence multiple pathological processes in GBM, including recurrence, drug resistance, and immune evasion. However, the role of TREM1 in mediating proneural-to-mesenchymal transition (PMT) in TAMs remains unclear. Methods: Single-cell RNA sequencing analysis of 24,366 cells from seven GBM patients identified nine distinct cellular populations, including TAMs and malignant cells. Deconvolution analysis of TCGA mRNA-seq data complemented these findings. Differential expression analysis, weighted gene co-expression network analysis, and LASSO-Cox regression consistently identified TREM1 in TAMs as a PMT-associated biomarker. A co-culture system demonstrated TREM1's influence on GBM cell malignancy and PMT progression in vitro, while intraperitoneal LP17 administration assessed its impact on tumor growth. Results: High TAM infiltration correlated significantly with poor clinical outcomes in GBM patients. Integrated scRNA-seq and mRNA-seq analyses established TREM1 in TAMs as a key PMT biomarker. LP17-mediated TREM1 inhibition attenuated PMT through modulation of the TLR4/PI3K/AKT/mTOR pathway and reduced tumor growth in vivo. Conclusion: TREM1 functions as an oncogenic biomarker in TAMs that drives GBM PMT via the TLR4/PI3K/AKT/mTOR axis, with inhibition of TREM1 demonstrating therapeutic potential in both ex vivo and in vivo models.
Keywords: TREM1, Glioblastoma, EMT, proneural-to-mesenchymal transition, tumour-associated macrophages
Received: 09 Jul 2025; Accepted: 17 Nov 2025.
Copyright: © 2025 Wang, Zhang, Hu, Hou and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shiqiang Hou, houshiqiang@ahmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.